Active, Not Recruiting
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia - CA209-7CK
Mis à jour: 25 janvier, 2022 | ClinicalTrials.gov
Sexe(s)
Tranche d’âge
Active, Not Recruiting
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Adults with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete surgical removal and have no evidence of disease - Decision to treat with adjuvant nivolumab therapy has already been taken - Ability to provide written informed consent to participate in the study Exclusion Criteria: - Adults with a current diagnosis of persisting advanced melanoma - Adults currently enrolled in an interventional clinical trial for his/her melanoma treatment Other protocol-defined inclusion/exclusion criteria apply
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
